Sustained release formulation of carbamazepine

Details Sustained release formulation of carbamazepine Sustained release formulation of carbamazepine

1999-04-15

2000-12-19

Spear, James M.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

424469, 424470, 424475, 424482, 514777, 514778, 514781, 514784, 514960, A61K 926, A61K 932

Patent

active

061624667

ABSTRACT:
The present invention provides a pharmaceutical preparation in tablet form, where the active ingredient is an anti-epileptic medication, preferably a sustained release formulation, and most preferably a sustained release formulation where the active ingredient is carbamazepine. The product consists of carbamazepine particles coated with a single hydrophobic layer and is in a disintegrating tablet form.

REFERENCES:
Bialer et al, "Criteria to Assess In Vivo Performance and Bioequivalence of Generic Controlled-Release Formulations of Carbamazepine", Epilepsia, 39(5): 513-519, 1998.
"Aqueous Polymeric Coatings for Pharaceutical Dosage Forms", ed. McGinity, JW, 2nd Ed., pp. 9-15, 55, 65, 73-81, 109-, 133, 169-189, 1992.

Affiliated with

Also associated with

Rating

Sustained release formulation of carbamazepine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sustained release formulation of carbamazepine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release formulation of carbamazepine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-269176